Screening Colorectal Cancer – Stool DNA Testing

After considering public comments and consulting with appropriate organizations, the Centers for Medicare & Medicaid Services (CMS) has determined that the evidence is sufficient to cover Cologuard™ – a multitarget stool DNA test – as a colorectal cancer screening test for asymptomatic, average risk beneficiaries, aged 50 to 85 years.

What this means: Medicare Part B will cover the Cologuard™ test once every three years for beneficiaries who meet all of the following criteria:

- Age 50 to 85 years,
- Asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test or fecal immunochemical test), and
- At average risk of developing colorectal cancer (no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease, including Crohn’s Disease and ulcerative colitis; no family history of colorectal cancers or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer).

All other screening stool DNA tests not otherwise specified above remain nationally non-covered.

Effective: October 9, 2014

For more information, contact Customer Services at the phone number on your member ID card.

This announcement can be found at Decision for Colorectal Cancer - Stool DNA Testing

H2456_022411_11 DHS Approved (02252011) CMS Approved (04062011)
H2459 H4270_022411_12 CMS Approved (04062011)
H2459 H4270 Group_022411_11 IA (02242011) U4174 (11/14)